Inflammation

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, April 3, 2024
Patient, SAN, Therapy, Cancer, Inflammation

SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, Nurix’s chief financial officer, and Jason Kantor, Ph.D., Nurix’s chief business officer, will participate in the following conferences in April:

Key Points: 
  • SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, Nurix’s chief financial officer, and Jason Kantor, Ph.D., Nurix’s chief business officer, will participate in the following conferences in April:
    Monday, April 8, 2024, from 11:00 – 11:40 a.m.
  • ET
    Fireside chat: Hans van Houte and Jason Kantor, Ph.D.
    Tuesday, April 16, 2024, from 1:00 – 1:25 p.m.
  • ET
    Piper Sandler Spring Biopharma Symposium (Boston, MA)
    Both fireside chats will be webcast live and may be accessed via links in the Investors section of the Nurix website under Events and Presentations .
  • The archived webcasts will be available on the Nurix website for 30 days after the event.

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Retrieved on: 
Wednesday, April 3, 2024
Clobetasol, Exchange, Infection, Acceleration, Refractive surgery, Inflammation, Annual general meeting, ASCRS, Patient, Private practice, Cataract, Society, Ophthalmology

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the company will be conducting demonstrations of its portfolio of commercial products at two upcoming ophthalmology medical meetings.

Key Points: 
  • “Our presence at national medical and commercial meetings like these are key to elevating awareness of our continuum of office-based and surgical products,” stated Michael Rowe, Eyenovia’s Chief Executive Officer.
  • These meetings complement the efforts of our field sales force in amplifying the synergistic nature of our product portfolio as well as the many benefits conferred to doctors and patients by the Optejet device.
  • Eyenovia will also be demonstrating Avenova and reviewing now-approved data on clobetasol, which complements the company’s surgical suite of products.
  • The event features continuing education, keynote speakers, Exchange-only pricing from more than 100 vendors, and opportunities to network with colleagues.

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

Retrieved on: 
Tuesday, April 2, 2024
Stargardt disease, Disease, Safety, Webcast, Inflammation, Patient, CGMP, Data, Inhalation, Cohort, RP, Life, Bank statement, Investment, Clinical trial, NIAID, Injection, AMD, Vaccine, Nextgen, Geographic atrophy, RHO, FDA, Lipid metabolism, Government, Oxidative stress, Pharmaceutical industry

Completed Cohort 1 dosing for OCU410 and OCU410ST gene therapy clinical studies for geographic atrophy (GA) and Stargardt disease, respectively

Key Points: 
  • Completed Cohort 1 dosing for OCU410 and OCU410ST gene therapy clinical studies for geographic atrophy (GA) and Stargardt disease, respectively
    MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today provided a general business update with certain financials for the year ending 2023.
  • During the fourth quarter of 2023, the Company announced its mucosal vaccine candidate, OCU500, was chosen for the multi-billion-dollar NIAID Project NextGen initiative.
  • The first patient was dosed in the Phase 1/2 trials to assess the safety and efficacy of OCU410ST for Stargardt disease in November 2023.
  • Ocugen’s cash, cash equivalents, and investments totaled $39.5 million as of December 31, 2023, compared to $90.9 million as of December 31, 2022.

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

Retrieved on: 
Tuesday, April 2, 2024
Disease, Macular edema, NIU, Paratriathlon, Arm, Rule, Safety, Risk, Webcast, Inflammation, Patient, NEPTUNE, EDT, Master of Science, Haze, Prednisone, Visual acuity, Therapy, Sumitomo Pharma, Calendar, Share repurchase, JAK, Visual impairment, Physician, Hand, Pediatrics, Pharmaceutical industry

We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma.

Key Points: 
  • We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma.
  • The NEPTUNE study enrolled 26 subjects with active NIU who were randomized 2:1 to brepocitinib 45 mg once daily or brepocitinib 15 mg once daily.
  • All week 24 secondary efficacy endpoints, including haze grades, visual acuity, and macular thickness, were also positive and dose responsive.
  • The presentation and webcast details are also available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events.

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

Retrieved on: 
Tuesday, April 2, 2024
Therapy, Patient, SAN, Gilead Sciences, Research, Rheumatoid arthritis, Cancer, IRAK4, Inflammation, Pharmaceutical industry

SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gilead Sciences has elected to extend the research term of the companies’ ongoing collaboration, originally established in 2019, by an additional two years.

Key Points: 
  • “Gilead’s extension of the research period of this agreement is a testament to the productivity of our collaboration to date.
  • Most importantly, it increases the opportunity for additional clinical candidates and associated milestones to emerge from our work together with the Gilead team,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix.
  • Gilead has an option to license drug candidates resulting from the work, and Nurix retains co-development and co-detail options on up to two programs in the United States, subject to certain restrictions.
  • Upon signing the agreement in 2019, Gilead made an upfront payment of $45.0 million.

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, April 2, 2024
Research, Failure, Plasma, KPMG, TDP43, Disease, PD, CSF, Yale University, Patient, Inflammation, Biomarker, CMC, Equity, TAR, Human, European, Drug development, ATM, Safety, Phase, Therapy, Vaccine, Treasury, Syneos Health, Axonal transport, Pharmaceutical industry

MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.

Key Points: 
  • MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.
  • For the quarter ended December 31, 2023, Annovis reported a net loss of $22.2 million, compared to a net loss of $7.7 million for the same period in 2022.
  • For the full year ended 2023, Annovis reported a net loss of $56.2 million, compared to a net loss of $25.3 million in 2022.
  • Other income (expense) for the quarter ended December 31, 2023 was ($11.2) million, compared to $0.2 million for the same period in 2022.

VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, April 2, 2024
Psoriasis, Defendant, News, IPO, Inflammation, Plaque, Prospectus, Complaint, Court, Person, Pharmaceutical industry

Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.

Key Points: 
  • Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.
  • The Company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.
  • On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

Retrieved on: 
Monday, April 1, 2024
Research, Court of Chancery, Notifiable disease, Ovarian cancer, JAMS, Prejudice, District court, Inflammation, Patient, Sale, News, G&A, University, Cancer, Trial of the century, Bank statement, Loss, Complaint, Pancreatic cancer, Patent, Probability, Court, Pharmaceutical industry

MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.
  • Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, “These are exciting times at HCW Biologics.
  • Revenues: Revenues for the fourth quarters ended December 31, 2022 and 2023 were $1.3 million and $1.3 million, respectively.
  • Net loss: Net loss for the fourth quarters ended December 31, 2022 and 2023 were $5.4 million and $10.7 million, respectively.

VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ventyx Biosciences, Inc.

Retrieved on: 
Monday, April 1, 2024
Psoriasis, District court, Defendant, News, IPO, Inflammation, Plaque, Complaint, Action Replay, Court, Advertising, Security (finance)

Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .

Key Points: 
  • Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 30, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Foundation for Sarcoidosis Research Launches Say Sarcoidosis Campaign to Shed Light on the 1.2 Million People Impacted by Sarcoidosis for April’s Awareness Month

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Disease, Organization, Prevalence, Caregiver, Patient, Knowledge, Social media, Research, FSR, Quality of life, Inflammation, Nursing

CHICAGO, April 01, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR), the leading international organization dedicated to finding a cure for sarcoidosis and improving care for patients, is proud to announce this year’s theme for April’s Sarcoidosis Awareness Month: Say Sarcoidosis. Sarcoidosis (pronounced SAR-COY-DOE-SIS) is an inflammatory disease of unknown cause characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organs of the body. Approximately 5-10% of all patients diagnosed will suffer from advanced sarcoidosis. Sarcoidosis affects the lungs in approximately 90% of cases, but it can affect almost any organ in the body and in more advanced or chronic cases can impact multiple organs at the same time. Despite its prevalence, sarcoidosis remains underrecognized and underdiagnosed, leading to delayed treatment and increased morbidity. It is estimated that 1.2 million people are affected worldwide. The Say Sarcoidosis campaign aims to shatter the silence and shine a light on the importance of speaking up about this often-misunderstood condition.

Key Points: 
  • CHICAGO, April 01, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR), the leading international organization dedicated to finding a cure for sarcoidosis and improving care for patients, is proud to announce this year’s theme for April’s Sarcoidosis Awareness Month: Say Sarcoidosis.
  • Approximately 5-10% of all patients diagnosed will suffer from advanced sarcoidosis.
  • The Say Sarcoidosis campaign aims to shatter the silence and shine a light on the importance of speaking up about this often-misunderstood condition.
  • For more information about Sarcoidosis Awareness Month and how to get involved with FSR’s Say Sarcoidosis campaign, please visit stopsarcoidosis.org/saysarcoidosis .